A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Tango Therapeutics, Inc.
Merck Sharp & Dohme LLC
TCR2 Therapeutics
TCR2 Therapeutics
Instituto do Cancer do Estado de São Paulo
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc